董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Philippe Weigerstorfer | 男 | Independent Director | 65 | 7.89万美元 | 0.51 | 2026-09-16 |
| Amy Trombly | 女 | Chief Executive Officer and Director | 59 | 74.11万美元 | 1.54 | 2026-09-16 |
| Vanessa Jacoby | 女 | Independent Director | 49 | 4.42万美元 | 未持股 | 2026-09-16 |
| Jerry McLaughlin | 男 | Lead Independent Director | 78 | 9.83万美元 | 0.53 | 2026-09-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Amy Trombly | 女 | Chief Executive Officer and Director | 59 | 74.11万美元 | 1.54 | 2026-09-16 |
| Jerry Dvonch | 男 | Chief Financial Officer | 57 | 42.27万美元 | 0.91 | 2026-09-16 |
董事简历
中英对照 | 中文 | 英文- Philippe Weigerstorfer
-
Philippe Weigerstorfer自2018年9月以来一直担任我们的董事会成员。他是Weigerstorfer New Venture LLC GmbH Switzerland的所有者和董事总经理。自2020年1月起，他担任新加坡Onycho Pharma Pte.Ltd.的董事会主席。从2011年到2017年底，Weigerstorfer先生担任Vifor Pharma Asia Pacific Pte Ltd的董事总经理，该公司是Vifor Pharma Group的一家公司，专门从事铁缺乏的治疗和预防，还包含传染病/OTX产品组合。作为董事总经理，Weigerstorfer先生负责管理Vifor Asia Pacific在新加坡的活动，并监督亚太地区。他自2008年起在Vifor Pharma工作。从2000年到2016年，他曾任职Galencia Ltd.，在那里他曾担任Galencia公司的执行主席的特别顾问，帮助通过收购制药公司、许可证和项目确保公司增长。从1996年到1999年，他曾任职Novartis Pharma Ltd.，在那里他曾领导皮肤科和其他领域的公司营销，并帮助Novartis公司成为世界领先的皮肤科公司之一。在此之前，Weigerstorfer先生曾在Sandoz Pharma AG担任许多不同的职务，包括皮肤科和心血管业务部的主管。他也曾任教于商学院。
Philippe Weigerstorfer has served on Sonoma Pharmaceuticals, Inc.'s Board of Directors since September 2018. He is the owner and managing director of Weigerstorfer New Venture LLC (GmbH) Switzerland. From 2011 until the end of 2017, Mr. Weigerstorfer was the managing director of Vifor Pharma Asia Pacific Pte Ltd, a company of the Vifor Pharma Group, which specializes in treatment and prevention of iron deficiencies and also contains an infectious diseases/OTX product portfolio. As managing director, Mr. Weigerstorfer was responsible for managing the activities of Vifor Asia Pacific in Singapore and overseeing the Asia Pacific region. He worked at Vifor Pharma since 2008. From 2000 to 2016, he worked at Galencia Ltd. where he rose to the position of Special Advisor to the executive Chairman of Galencia, helping ensure corporate growth through acquisition of pharmaceutical companies, licenses, and projects. From 1996 to 1999 he worked at Novartis Pharma Ltd. where he headed the corporate marketing for the "dermatology and others" area and helped Novartis to become one of the leading dermatology companies in the world. Previous to that, Mr. Weigerstorfer worked with Sandoz Pharma AG in many different roles including as head of the dermatology and cardiovascular business unit. He also taught at business school.Degree in Business Administration and Economics from University Basel,Minor in Law from University Basel. - Philippe Weigerstorfer自2018年9月以来一直担任我们的董事会成员。他是Weigerstorfer New Venture LLC GmbH Switzerland的所有者和董事总经理。自2020年1月起，他担任新加坡Onycho Pharma Pte.Ltd.的董事会主席。从2011年到2017年底，Weigerstorfer先生担任Vifor Pharma Asia Pacific Pte Ltd的董事总经理，该公司是Vifor Pharma Group的一家公司，专门从事铁缺乏的治疗和预防，还包含传染病/OTX产品组合。作为董事总经理，Weigerstorfer先生负责管理Vifor Asia Pacific在新加坡的活动，并监督亚太地区。他自2008年起在Vifor Pharma工作。从2000年到2016年，他曾任职Galencia Ltd.，在那里他曾担任Galencia公司的执行主席的特别顾问，帮助通过收购制药公司、许可证和项目确保公司增长。从1996年到1999年，他曾任职Novartis Pharma Ltd.，在那里他曾领导皮肤科和其他领域的公司营销，并帮助Novartis公司成为世界领先的皮肤科公司之一。在此之前，Weigerstorfer先生曾在Sandoz Pharma AG担任许多不同的职务，包括皮肤科和心血管业务部的主管。他也曾任教于商学院。
- Philippe Weigerstorfer has served on Sonoma Pharmaceuticals, Inc.'s Board of Directors since September 2018. He is the owner and managing director of Weigerstorfer New Venture LLC (GmbH) Switzerland. From 2011 until the end of 2017, Mr. Weigerstorfer was the managing director of Vifor Pharma Asia Pacific Pte Ltd, a company of the Vifor Pharma Group, which specializes in treatment and prevention of iron deficiencies and also contains an infectious diseases/OTX product portfolio. As managing director, Mr. Weigerstorfer was responsible for managing the activities of Vifor Asia Pacific in Singapore and overseeing the Asia Pacific region. He worked at Vifor Pharma since 2008. From 2000 to 2016, he worked at Galencia Ltd. where he rose to the position of Special Advisor to the executive Chairman of Galencia, helping ensure corporate growth through acquisition of pharmaceutical companies, licenses, and projects. From 1996 to 1999 he worked at Novartis Pharma Ltd. where he headed the corporate marketing for the "dermatology and others" area and helped Novartis to become one of the leading dermatology companies in the world. Previous to that, Mr. Weigerstorfer worked with Sandoz Pharma AG in many different roles including as head of the dermatology and cardiovascular business unit. He also taught at business school.Degree in Business Administration and Economics from University Basel,Minor in Law from University Basel.
- Amy Trombly
-
Amy Trombly自2019年9月27日起担任我们的首席执行官。她在公司和证券法和并购方面为上市公司提供咨询长达二十年。她自2002年起拥有和管理Trombly Business Law，PC。在她早期的职业生涯中，特罗姆布利是道富银行（State Street Bank）的Vice President，也是美国证券交易委员会（U.S.Commission）的特别顾问。
Amy Trombly has been Sonoma Pharmaceuticals, Inc.'s Chief Executive Officer since September 27, 2019. She has counseled public companies for two decades in corporate and securities law and mergers and acquisitions. She owned and managed Trombly Business Law, PC from 2002 to 2022. In her earlier career, Ms. Trombly was a Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission.BS in Finance from Babson College,J.D. from Suffolk University Law School,Member of the bar in Massachusetts and Colorado. - Amy Trombly自2019年9月27日起担任我们的首席执行官。她在公司和证券法和并购方面为上市公司提供咨询长达二十年。她自2002年起拥有和管理Trombly Business Law，PC。在她早期的职业生涯中，特罗姆布利是道富银行（State Street Bank）的Vice President，也是美国证券交易委员会（U.S.Commission）的特别顾问。
- Amy Trombly has been Sonoma Pharmaceuticals, Inc.'s Chief Executive Officer since September 27, 2019. She has counseled public companies for two decades in corporate and securities law and mergers and acquisitions. She owned and managed Trombly Business Law, PC from 2002 to 2022. In her earlier career, Ms. Trombly was a Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission.BS in Finance from Babson College,J.D. from Suffolk University Law School,Member of the bar in Massachusetts and Colorado.
- Vanessa Jacoby
-
Vanessa Jacoby，目前担任Quanta Therapeutics，Inc.的首席业务和财务官，该公司是一家临床阶段的生物技术公司，专注于为RAS驱动的癌症开发一流的小分子抑制剂。在加入广达之前，Jacoby女士曾担任Shoreline Biosciences的首席财务官。在加入Shoreline之前，Jacoby女士曾在Avidity Biosciences, Inc.担任首席会计官。在Avidity加入之前，Jacoby女士是PharmAKEA的财务副总裁，该公司于2019年被Galecto收购。在此之前，她曾在BCI，Inc.担任会计总监和财务总监，并曾在Artes Medical和Verenium化工担任高级财务职务。在加入行业之前，Jacoby女士是安永会计师事务所的审计师。Jacoby女士获得了国立大学的工商管理硕士学位和巴西圣保罗Funda o Armando Alvares Penteado的工商管理学士学位。她是加利福尼亚州的注册会计师（非在职）。她目前担任圣地亚哥Ruben H. Fleet科学中心的董事会成员，并担任生物科学财务官员协会（ABFO）西南分会的董事会成员。
Vanessa Jacoby serves as the Chief Business and Financial Officer for Quanta Therapeutics, Inc., a clinical stage biotechnology company focused on developing best in class small molecles inhibitors for RAS driven cancers. Prior to joining Quanta, Ms. Jacoby served as Chief Financial Officer of Shoreline Biosciences. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc. Prior to Avidity, Ms. Jacoby was Vice President, Finance at PharmAkea, which was acquired by Galecto in 2019. Prior to that, she served as Director of Accounting and Controller at BCI, Inc., and held senior financial roles at Artes Medical and Verenium Corporation. Before joining industry, Ms. Jacoby was an auditor for Ernst & Young. She currently serves on the board of trustees for the Ruben H. Fleet Science Center in San Diego and is on the board for the Association of Bioscience Financial Officers (ABFO) Southwest chapter.B.S. degree in Business Administration from Fundacio Armando Alvares Penteado, Sao Paulo, Brazil,M.B.A. from National University,Certified Public Accountant with the State of California (inactive). - Vanessa Jacoby，目前担任Quanta Therapeutics，Inc.的首席业务和财务官，该公司是一家临床阶段的生物技术公司，专注于为RAS驱动的癌症开发一流的小分子抑制剂。在加入广达之前，Jacoby女士曾担任Shoreline Biosciences的首席财务官。在加入Shoreline之前，Jacoby女士曾在Avidity Biosciences, Inc.担任首席会计官。在Avidity加入之前，Jacoby女士是PharmAKEA的财务副总裁，该公司于2019年被Galecto收购。在此之前，她曾在BCI，Inc.担任会计总监和财务总监，并曾在Artes Medical和Verenium化工担任高级财务职务。在加入行业之前，Jacoby女士是安永会计师事务所的审计师。Jacoby女士获得了国立大学的工商管理硕士学位和巴西圣保罗Funda o Armando Alvares Penteado的工商管理学士学位。她是加利福尼亚州的注册会计师（非在职）。她目前担任圣地亚哥Ruben H. Fleet科学中心的董事会成员，并担任生物科学财务官员协会（ABFO）西南分会的董事会成员。
- Vanessa Jacoby serves as the Chief Business and Financial Officer for Quanta Therapeutics, Inc., a clinical stage biotechnology company focused on developing best in class small molecles inhibitors for RAS driven cancers. Prior to joining Quanta, Ms. Jacoby served as Chief Financial Officer of Shoreline Biosciences. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc. Prior to Avidity, Ms. Jacoby was Vice President, Finance at PharmAkea, which was acquired by Galecto in 2019. Prior to that, she served as Director of Accounting and Controller at BCI, Inc., and held senior financial roles at Artes Medical and Verenium Corporation. Before joining industry, Ms. Jacoby was an auditor for Ernst & Young. She currently serves on the board of trustees for the Ruben H. Fleet Science Center in San Diego and is on the board for the Association of Bioscience Financial Officers (ABFO) Southwest chapter.B.S. degree in Business Administration from Fundacio Armando Alvares Penteado, Sao Paulo, Brazil,M.B.A. from National University,Certified Public Accountant with the State of California (inactive).
- Jerry McLaughlin
-
Jerry McLaughlin 自2011年11月至2013年4月担任了Applied BioCode的临时首席执行官。2011年4月，他也建立并成为现为数据流医学成像系统公司的总裁和首席执行官，负责启动开发诊断成像的应用软件与现有的数字化平台一起工作。自2007年7月至2011年12月，他曾担任DataFlow Information Systems的总裁。自2002年5月至2007年6月，他担任了CompuMed总裁和首席执行官。McLaughlin先生也是 DataStream Medical Imaging Systems（一个医疗成像软件行业的私企）和DataFlow Information Systems（一个医疗器械行业的国企）的董事会成员之一。
Jerry McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded, and until April 2016, served as Chairman of the Board and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin has also served in senior level marketing and sales positions at Boehringer Mannheim Diagnostics (acquired by Roche Diagnostics), UniPath (medical division of Unilever) and Diagnostic Products Corporation (acquired by Siemens).B.S. in Pharmacy from State University of New York at Buffalo. - Jerry McLaughlin 自2011年11月至2013年4月担任了Applied BioCode的临时首席执行官。2011年4月，他也建立并成为现为数据流医学成像系统公司的总裁和首席执行官，负责启动开发诊断成像的应用软件与现有的数字化平台一起工作。自2007年7月至2011年12月，他曾担任DataFlow Information Systems的总裁。自2002年5月至2007年6月，他担任了CompuMed总裁和首席执行官。McLaughlin先生也是 DataStream Medical Imaging Systems（一个医疗成像软件行业的私企）和DataFlow Information Systems（一个医疗器械行业的国企）的董事会成员之一。
- Jerry McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded, and until April 2016, served as Chairman of the Board and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin has also served in senior level marketing and sales positions at Boehringer Mannheim Diagnostics (acquired by Roche Diagnostics), UniPath (medical division of Unilever) and Diagnostic Products Corporation (acquired by Siemens).B.S. in Pharmacy from State University of New York at Buffalo.
高管简历
中英对照 | 中文 | 英文- Amy Trombly
Amy Trombly自2019年9月27日起担任我们的首席执行官。她在公司和证券法和并购方面为上市公司提供咨询长达二十年。她自2002年起拥有和管理Trombly Business Law，PC。在她早期的职业生涯中，特罗姆布利是道富银行（State Street Bank）的Vice President，也是美国证券交易委员会（U.S.Commission）的特别顾问。
Amy Trombly has been Sonoma Pharmaceuticals, Inc.'s Chief Executive Officer since September 27, 2019. She has counseled public companies for two decades in corporate and securities law and mergers and acquisitions. She owned and managed Trombly Business Law, PC from 2002 to 2022. In her earlier career, Ms. Trombly was a Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission.BS in Finance from Babson College,J.D. from Suffolk University Law School,Member of the bar in Massachusetts and Colorado.- Amy Trombly自2019年9月27日起担任我们的首席执行官。她在公司和证券法和并购方面为上市公司提供咨询长达二十年。她自2002年起拥有和管理Trombly Business Law，PC。在她早期的职业生涯中，特罗姆布利是道富银行（State Street Bank）的Vice President，也是美国证券交易委员会（U.S.Commission）的特别顾问。
- Amy Trombly has been Sonoma Pharmaceuticals, Inc.'s Chief Executive Officer since September 27, 2019. She has counseled public companies for two decades in corporate and securities law and mergers and acquisitions. She owned and managed Trombly Business Law, PC from 2002 to 2022. In her earlier career, Ms. Trombly was a Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission.BS in Finance from Babson College,J.D. from Suffolk University Law School,Member of the bar in Massachusetts and Colorado.
- Jerry Dvonch
Jerry Dvonch于2020年9月8日被任命为我们的首席财务官。从2017年3月到2020年8月，他是Spinecenter Atlanta的财务和会计总监和高级副总裁。从2016年3月到2016年4月，他是DS医疗保健Group，Inc.的顾问总监。此前，他曾担任Neogenomics Laboratories的外部报告总监和财务总监（从2005年7月到2015年7月）。他拥有超过10年的SEC报告经验。尼亚加拉大学会计工商管理学士学位。罗切斯特大学金融工商管理硕士学位。纽约注册会计师。
Jerry Dvonch was appointed as Sonoma Pharmaceuticals, Inc.'s Chief Financial Officer on February 7, 2024, after serving as Sonoma Pharmaceuticals, Inc.'s Interim Chief Financial Officer since April 7, 2023. He also served as Sonoma Pharmaceuticals, Inc.'s Chief Financial Officer from September 2020 to November 2022. From March 2017 to August 2020, he was the controller and Senior Vice President of Finance and Accounting of the SpineCenter Atlanta. From March 2016 to April 2016, he was a consultant controller for DS Healthcare Group, Inc. Prior to that he was the director for external reporting and director of finance of NeoGenomics Laboratories from July 2005 to July 2015. He has over 15 years of experience with SEC reporting.Bachelor of Business Administration in Accounting from Niagara University,Master of Business Administration in Finance from University of Rochester,Certified Public Accountant in New York.- Jerry Dvonch于2020年9月8日被任命为我们的首席财务官。从2017年3月到2020年8月，他是Spinecenter Atlanta的财务和会计总监和高级副总裁。从2016年3月到2016年4月，他是DS医疗保健Group，Inc.的顾问总监。此前，他曾担任Neogenomics Laboratories的外部报告总监和财务总监（从2005年7月到2015年7月）。他拥有超过10年的SEC报告经验。尼亚加拉大学会计工商管理学士学位。罗切斯特大学金融工商管理硕士学位。纽约注册会计师。
- Jerry Dvonch was appointed as Sonoma Pharmaceuticals, Inc.'s Chief Financial Officer on February 7, 2024, after serving as Sonoma Pharmaceuticals, Inc.'s Interim Chief Financial Officer since April 7, 2023. He also served as Sonoma Pharmaceuticals, Inc.'s Chief Financial Officer from September 2020 to November 2022. From March 2017 to August 2020, he was the controller and Senior Vice President of Finance and Accounting of the SpineCenter Atlanta. From March 2016 to April 2016, he was a consultant controller for DS Healthcare Group, Inc. Prior to that he was the director for external reporting and director of finance of NeoGenomics Laboratories from July 2005 to July 2015. He has over 15 years of experience with SEC reporting.Bachelor of Business Administration in Accounting from Niagara University,Master of Business Administration in Finance from University of Rochester,Certified Public Accountant in New York.